University of Sydney School of Medicine, Australia
Fazlul Huq is currently working as Assosciate proffesor in Biomedical Sciences, The university of Sydney, Australia.
He has teaching experience in toxicology, biochemistry and biophysics to students of Health Sciences.
Fazlul Huq leads cancer research in the Discipline of Biomedical Science Sydney Medical School working on drug design and drug combination towards overcoming drug resistance in ovarian and colorectal cancers.
He is also an accomplished poet with over 16500 compositions covering diverse themes including life, science, society and philosophy
Professor Adrian was trained at the Royal Postgraduate Medical School (Imperial College School of Medicine) in London where he received his PhD and his MRCPath. He moved to Yale University as Director of the GI Surgical Research Laboratory, then to Creighton University in Omaha, Nebraska as Professor and Head of the Physiology Division and Research Director in the Cancer Center and then to Northwestern University School of Medicine in Chicago, where he was Professor and Director of Gastrointestinal Cancer Research. In 2006, he moved to Al Ain as Chairman of the Department of Physiology, in the College of Medicine at the United Arab Emirates University. He joined Mohammed Bin Rashid University of Medicine and Health Sciences in 2018. Professor Adrian has published more than 400 scholarly articles in peer-reviewed journals (Citations >25,000; h-index = 79) and more than 80 reviews and book chapters.
Chakrabarty is a Distinguished University Professor in the Department of Microbiology and Immunology in the University of Illinois at Chicago College of Medicine. Apart from being an eminent scientist, Ananda Chakrabarty has been an advisor to judges, governments, and the United Nations. As one of the founding members of a United Nations Industrial Development Organization committee that proposed the establishment of the International Centre for Genetic Engineering and Biotechnology, he has been a member of its Council of Scientific Advisors ever since. He has served the U.S. government as a member of NIH Study Sections, a member of the Board on Biology of the National Academy of Science, and the Committee on Biotechnology of the National Research Council. Currently, his lab is working on elucidating the role of bacterial cupredoxins and cytochromes in cancer regression and arresting cell cycle progression.
Dr. Luo has been studying molecular mechanisms of human malignancies in the last 32 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 20 years, Dr. Luo has been largely focusing on thegenetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MCM8, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 epigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7, MCM7-SF3B3and MCM8-cyclin D1 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, his group discovered several novel fusion transcripts and their association with aggressive prostate cancer. Subsequently, his group discovered that many of these fusion genes are recurrent in many other types of human cancers. One of the fusion genes called MAN2A1-FER, was found present in 6 different types of human cancers. He later defined a critical MAN2A1-FER/EGFR signaling pathway through ectopic phosphorylation that is essential for MAN2A1-FER mediated transformation activity. His group also developed a genome intervention strategy targeting at the chromosomal breakpoint of fusion gene to treat cancers. Overall, these findings advance our understanding of how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.
The University of Texas MD Anderson Cancer Center, USA
The University of Texas MD Anderson Cancer Center, USA
Dr. Shiaw-Yih (Phoebus) Lin is a tenured professor and Deputy Chair of Department of Systems Biology at The University of Texas MD Anderson Cancer Center. Dr. Linâ€™s research efforts are focused within an overall theme of DNA damage response defects in cancer with the specific emphasis on systems and translational precision cancer therapy. Dr. Lin serves on editorial boards of ten international journals and has served on numerous grant review committees for NIH, DOD and other funding organizations both nationally and internationally.
Faculty of Medicine of Tunis- El Manar University of Tunis-Tunisia. TUNISIA
ACHOUR Radhouane is associate professor at faculty of medicine of Tunis-Tunisia; He has published many basic and clinical articles in relation to gynecology and obstetrics. , his research interests include Rare Diseases in gynecology and prenatal diagnosis.
He serves as associate professor, Emergency Department of Gynecology and Obstetrics in maternity and neonatology center Tunis Tunisia.
Dr. Dyer current academic and clinical positions give her a broad set of expertise in both the practice and teaching of surgical disciplines. She works in the fields of general surgery and breast surgical oncology. Her role in medical education spans curriculum development, to teaching medical students clinical skills. Over the course of her career, Dr. Dyer has gained a wide range of experience including working in breast surgery outpatient clinics, head and neck surgery, breast reconstructive surgery, hand surgery, and trauma through positions in hospital centers in the United States, United Kingdom, France, and the Caribbean.
Dr. Shafikhani is an Associate Professor in the Department of Medicine, Division of Hematology, Oncology, and Cell therapy at Rush University Medical Center. Dr. Shafikhaniâ€™s group is interested in understanding how the presence of tumor and infection lead to a state of immune-confusion affecting both anti-tumor and anti-bacterial immune defenses. His group is also interested in developing bacterial toxins as effective anti-cancer therapeutics. His group is also interested in innate immune dysregulation that renders diabetic wounds vulnerable to infection.
Lipin Kao (Betty), a certified project manager, received her Ph.D. in Biomedical Engineering from Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Australia and postdoctoral studies in Cancer Biology. Her thesis focused on the mitochondrial role in human embryonic stem cells. She has extensive publications in reputed journals, covered genetic expression profile, cell biology (stem cells, and cancer cells), mitochondrial biology, cancer biology, neuroscience, toxicology, and pharmacology, and has been serving as an reviewer and an editorial board member of repute.